A Study of DCC-2701 in Participants With Advanced Solid Tumors

This is a first-in-human study of DCC-2701. The primary purpose of this study is to determine
what dose of DCC-2701, can be given safely to patients with advanced solid tumors.

The study will have two phases. The first phase will assess escalating doses of DCC-2701 in
order to determine the maximally tolerated dose (MTD) and the optimal dosing regimen (ODR) of
DCC-2701. Once the MTD and ODR is established, a dose expansion phase will further evaluate
the safety of DCC-2701, as well as the activity of DCC-2701 in select solid tumor types.

Inclusion Criteria:

- Advanced or metastatic solid tumor that has progressed or was not responsive to
standard therapy

- The cancer has no proven effective therapy

- The cancer can be biopsied (depending on the tumor type and/or the dose of drug
received, tumor biopsies may be required)

- Able to swallow tablets

Exclusion Criteria:

- Have active central nervous system (CNS) metastasis

- Have an active infection of any kind (fungal, viral, or bacterial)

- Are pregnant or breastfeeding